MRK | Weekly | Haru Insights

Merck’s FDA approval of KEYTRUDA in combination with Padcev for muscle-invasive bladder cancer—marking the first and only PD-1 inhibitor/ADC regimen approved in both neoadjuvant and adjuvant settings regardless of cisplatin eligibility—solidifies MRK’s leadership in combination immuno-oncology and opens a broad, high-need market.
The upcoming earnings release on August 4, 2026, looms as the most critical event, with a projected 42%+ decline in full-year profits despite revenue gains, putting MRK’s premium valuation under intense scrutiny.

The landmark FDA approval of KEYTRUDA + Padcev for bladder cancer establishes a transformative competitive moat, positioning MRK as the undisputed leader in combination immuno-oncology and capturing a vast, high-need patient population.
The $6.7 billion acquisition of Terns Pharmaceutical reflects aggressive confidence in long-term innovation, significantly bolstering MRK’s pipeline with promising targeted therapies like TERN-701 across multiple cancers.
Outperformance in HDV and sustained leadership in PPH underscore strong market confidence, proving MRK remains a top-tier income and total return generator despite near-term headwinds.
The approved regimen’s broad eligibility—bypassing cisplatin constraints—expands access to a critical patient cohort, dramatically increasing potential market penetration and therapeutic impact.
MRK’s continued dominance in immuno-oncology innovation reaffirms its role as a driver of next-generation cancer treatments, reinforcing long-term franchise strength.

Merck & Co., Inc. (MRK)[Tv]